Karyopharm Therapeutics Inc
KPTI5.360USD
-0.290-5.13%
Handelsschluss 11/05, 16:00（ET）Kurse um 15 Minuten verzögert
46.64MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Karyopharm Therapeutics Inc Unternehmen
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Inc Informationen
BörsenkürzelKPTI
Name des UnternehmensKaryopharm Therapeutics Inc
IPO-datumNov 06, 2013
CEOMr. Richard A. Paulson
Anzahl der mitarbeiter279
WertpapierartOrdinary Share
GeschäftsjahresendeNov 06
Addresse85 Wells Avenue
StadtNEWTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02459
Telefon16176580600
Websitehttps://karyopharm.com/
BörsenkürzelKPTI
IPO-datumNov 06, 2013
CEOMr. Richard A. Paulson
Führungskräfte von Karyopharm Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
55.93K
+355.57%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
48.29K
+460.88%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Ms. Lori Macomber, CPA
Ms. Lori Macomber, CPA
Executive Vice President, Chief Financial Officer, Treasurer
Executive Vice President, Chief Financial Officer, Treasurer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
55.93K
+355.57%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
48.29K
+460.88%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Nov 1
Aktualisiert: Sat, Nov 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Opaleye Management Inc.
5.57%
J. Wood Capital Advisors LLC
4.60%
T. Rowe Price Investment Management, Inc.
4.27%
J.P. Morgan Securities LLC
2.51%
Adage Capital Management, L.P.
2.47%
Andere
80.57%
Aktionäre
Aktionäre
Anteil
Opaleye Management Inc.
5.57%
J. Wood Capital Advisors LLC
4.60%
T. Rowe Price Investment Management, Inc.
4.27%
J.P. Morgan Securities LLC
2.51%
Adage Capital Management, L.P.
2.47%
Andere
80.57%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
14.86%
Investment Advisor
10.63%
Research Firm
5.50%
Investment Advisor/Hedge Fund
3.08%
Corporation
2.88%
Individual Investor
2.49%
Venture Capital
1.00%
Bank and Trust
0.01%
Andere
59.55%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
250
4.64M
29.19%
-677.45K
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
J. Wood Capital Advisors LLC
458.13K
5.28%
--
--
Apr 10, 2025
T. Rowe Price Investment Management, Inc.
728.77K
8.4%
+589.12K
+421.87%
Jun 30, 2025
J.P. Morgan Securities LLC
256.44K
2.96%
+109.02K
+73.95%
Jun 30, 2025
Adage Capital Management, L.P.
421.32K
4.86%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
518.27K
5.98%
+7.97K
+1.56%
Jun 30, 2025
Eversept Partners, LP
257.15K
2.97%
--
--
Jun 30, 2025
Citadel Advisors LLC
206.78K
2.38%
-128.00
-0.06%
Jun 30, 2025
Palo Alto Investors LP
187.91K
2.17%
-136.12K
-42.01%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
184.85K
2.13%
-3.16K
-1.68%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.01%
Global X Russell 2000 Covered Call ETF
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
Fidelity Enhanced Small Cap ETF
Anteil0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Datum
Art
Verhältnis
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
